Showing results (201-210 of 233) with videos related to

Sort By:
Pageof 24
Genome Research|December 22, 2021
Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancersAneta Mikulasova, Daniel Kent, Marco Trevisan-Herraz, et al.
Molecular Cancer Therapeutics|September 3, 2009
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myelomaFrits van Rhee, Susann M Szmania, Myles Dillon, et al.
Journal of Clinical Medicine|March 25, 2022
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital AdmissionKristin Larsen, Horace Spencer, Meera Mohan, et al.
Haematologica|March 16, 2012
Highly activated and expanded natural killer cells for multiple myeloma immunotherapyTarun K Garg, Susann M Szmania, Junaid A Khan, et al.
British Journal of Haematology|August 28, 2024
Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodiesOthman Salim Akhtar, Aniko Szabo, Vineel Bhatlapenumarthi, et al.
The Lancet. Oncology|July 22, 2014
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trialFrits van Rhee, Raymond S Wong, Nikhil Munshi, et al.
Nature Communications|January 13, 2021
The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myelomaEileen M Boyle, Shayu Deshpande, Ruslana Tytarenko, et al.
Blood|May 23, 2018
The presence of large focal lesions is a strong independent prognostic factor in multiple myelomaLeo Rasche, Edgardo J Angtuaco, Terri L Alpe, et al.
Experimental Hematology & Oncology|August 23, 2025
Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibitionHayley M Sabol, Aric Anloague, Japneet Kaur, et al.
Pageof 24